| 1 | 1 | | LRB-2616/1 |
|---|
| 2 | 2 | | KMS:cdc |
|---|
| 3 | 3 | | 2023 - 2024 LEGISLATURE |
|---|
| 4 | 4 | | 2023 ASSEMBLY JOINT RESOLUTIO N 33 |
|---|
| 5 | 5 | | April 18, 2023 - Introduced by Representatives ROZAR, C. ANDERSON, DRAKE, |
|---|
| 6 | 6 | | EMERSON, MAGNAFICI, MOSES, MURPHY, OHNSTAD, SHANKLAND and SINICKI, |
|---|
| 7 | 7 | | cosponsored by Senators CABRAL-GUEVARA and FELZKOWSKI. Referred to |
|---|
| 8 | 8 | | Committee on Rules. |
|---|
| 9 | 9 | | ***AUTHORS SUBJECT TO CHANGE*** |
|---|
| 10 | 10 | | Relating to: proclaiming May 1 to 7, 2023, as Tardive Dyskinesia Awareness Week |
|---|
| 11 | 11 | | in Wisconsin. |
|---|
| 12 | 12 | | Whereas, many people with serious mental health conditions, such as bipolar |
|---|
| 13 | 13 | | disorder, major depression, schizophrenia, and schizoaffective disorder, or |
|---|
| 14 | 14 | | gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be |
|---|
| 15 | 15 | | treated with medications that work as dopamine receptor blocking agents (DRBAs), |
|---|
| 16 | 16 | | including antipsychotics; and |
|---|
| 17 | 17 | | Whereas, while ongoing treatment with these medications can be necessary, |
|---|
| 18 | 18 | | prolonged use can also lead to tardive dyskinesia (TD), an involuntary movement |
|---|
| 19 | 19 | | disorder that is characterized by uncontrollable, abnormal, and repetitive |
|---|
| 20 | 20 | | movements of the face, torso, or other body parts; and |
|---|
| 21 | 21 | | Whereas, it is estimated that TD affects approximately 600,000 people in the |
|---|
| 22 | 22 | | United States, and approximately 70 percent of people with TD have not been |
|---|
| 23 | 23 | | diagnosed, making it important to raise awareness about the symptoms and impact |
|---|
| 24 | 24 | | 1 |
|---|
| 25 | 25 | | 2 |
|---|
| 26 | 26 | | 3 |
|---|
| 27 | 27 | | 4 |
|---|
| 28 | 28 | | 5 |
|---|
| 29 | 29 | | 6 |
|---|
| 30 | 30 | | 7 |
|---|
| 31 | 31 | | 8 |
|---|
| 32 | 32 | | 9 |
|---|
| 33 | 33 | | 10 |
|---|
| 34 | 34 | | 11 |
|---|
| 35 | 35 | | 12 |
|---|
| 36 | 36 | | 13 |
|---|
| 37 | 37 | | 14 - 2 - |
|---|
| 38 | 38 | | LRB-2616/1 |
|---|
| 39 | 39 | | KMS:cdc |
|---|
| 40 | 40 | | 2023 - 2024 Legislature |
|---|
| 41 | 41 | | of TD because even mild symptoms of TD can have physical, social, and emotional |
|---|
| 42 | 42 | | consequences; and |
|---|
| 43 | 43 | | Whereas, it is important that people taking DRBA medication be monitored for |
|---|
| 44 | 44 | | TD. Regular screening for TD in these patients is recommended by the American |
|---|
| 45 | 45 | | Psychiatric Association; and |
|---|
| 46 | 46 | | Whereas, clinical research has led to the availability of two treatments for |
|---|
| 47 | 47 | | adults with TD approved by the U.S. Food and Drug Administration; and |
|---|
| 48 | 48 | | Whereas, the legislature can raise awareness of TD in the public and medical |
|---|
| 49 | 49 | | community; now, therefore, be it |
|---|
| 50 | 50 | | Resolved by the assembly, the senate concurring, That the legislature does |
|---|
| 51 | 51 | | hereby proclaim May 1 to 7, 2023, to be Tardive Dyskinesia Awareness Week in |
|---|
| 52 | 52 | | Wisconsin; and be it further |
|---|
| 53 | 53 | | Resolved, That the legislature encourages each individual in the state of |
|---|
| 54 | 54 | | Wisconsin to become better informed about and aware of tardive dyskinesia. |
|---|
| 55 | 55 | | (END) |
|---|
| 56 | 56 | | 1 |
|---|
| 57 | 57 | | 2 |
|---|
| 58 | 58 | | 3 |
|---|
| 59 | 59 | | 4 |
|---|
| 60 | 60 | | 5 |
|---|
| 61 | 61 | | 6 |
|---|
| 62 | 62 | | 7 |
|---|
| 63 | 63 | | 8 |
|---|
| 64 | 64 | | 9 |
|---|
| 65 | 65 | | 10 |
|---|
| 66 | 66 | | 11 |
|---|
| 67 | 67 | | 12 |
|---|
| 68 | 68 | | 13 |
|---|
| 69 | 69 | | 14 |
|---|
| 70 | 70 | | 15 |
|---|